Clinical Trial Update: Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating recombinant human thrombopoietin with rituximab versus high-dose dexamethasone for initial treatment of primary immune thrombocytopen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Rituxan (rituximab)
• rhTPO (recombinant human thrombopoietin)

Snippet

Sponsor: Shandong University | Conditions: Purpura, Idiopathic Thrombocytopenic Purpura | Phase 3 | Status: WITHDRAWN